Partnering
Our partnering approach
In line with our vision to establish DARPins as state-of-the-art binding proteins, we strive to enable our partners with our Athebody® DARPin technology in the best possible way and according to their individual needs. This can range from giving access to our know-how and proprietary Athebody® DARPin technology, to selecting custom Athebody® DARPin building blocks, to setting up an inhouse Athebody® DARPin selection machinery for our partners. Looking forward to discussing your ideas!
“Alone we can do so little; together we can do so much.”
Our collaborations
POINT Biopharma and Athebio announce partnership
Athebio Enters Development and License Agreement with Acuitas Therapeutics
Athebio and POINT Biopharma enter into a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands (“Radio-DARPins”).
Read more here
Athebio and Acuitas Therapeutics enter into development and license agreement to explore the potential of combining Athebio’s Athebody® DARPins and Acuitas’ LNP technology for targeted nucleic acid delivery using DARPin-LNP and make it accessible to Acuitas’ partners.
Read more here
Athebio Enters Research Agreement with REGENXBIO
Athebio and REGENXBIO enter into research agreement to develop novel, targeted, adeno-associated virus (AAV) vectors that combine Athebio's proprietary Athebody® DARPin Platform and REGENXBIO’s NAV® Technology Platform.
Read more here
Athebio Enters Collaboration Agreement with 3T Biosciences
Athebio has entered into a collaboration agreement with 3T Biosciences, an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response guided target discovery approach.
Read more here
